---
document_datetime: 2023-09-21 20:31:55
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ulipristal-acetate-gedeon-richter-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ulipristal-acetate-gedeon-richter-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.33562
conversion_datetime: 2025-12-20 18:19:01.865854
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EMA/66011/2021

## Ulipristal Acetate Gedeon Richter

<!-- image -->

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                               |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| A31/0002             | Pursuant to Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data, on 5 March 2020, the European Commission requested the European Medicines Agency to assess the risk of severe liver injury and their impact on the benefit- | 12/11/2020                          | 11/01/2021                                  | SmPC, Annex II, Labelling and PL | Please refer to the CHMP scientific conclusions and PRAC assessment report: Ulipristal acetate 5mg: EMEA/H/A- 31/1496 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | risk balance of ulipristal acetate 5mg and to give its opinion, on whether the marketing authorisations for ulipristal acetate 5mg medicinal products should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion was adopted on the basis of an assessment by the Pharmacovigilance Risk Assessment Committee.   |            | authorised                        |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------|
| PSUSA/9325/ 201902 | Periodic Safety Update EU Single assessment - ulipristal acetate (treatment of moderate to severe symptoms of uterine fibroids)                                                                                                                                                                                                                                                                                            | 05/09/2019 | PRAC Recommendation - maintenance |

<!-- image -->